Cyclodex

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cyclodex

Quick Facts

Property Description
Active ingredient Piroxicam
Form Inclusion complex (Piroxicam-beta-cyclodextrin)
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
Common use Relief of pain and inflammation
Origin Synthetic/Derived

What Type of Medicine is Cyclodex?

Cyclodex is a specific pharmaceutical preparation that functions as a Nonsteroidal Anti-inflammatory Drug (NSAID), primarily used to relieve pain and reduce swelling by modulating inflammatory processes. This medicine is chemically defined as the Piroxicam-beta-cyclodextrin complex, and it belongs to the oxicam class of NSAIDs. The core active compound is Piroxicam, which is an agent clinically recognized for its reliable analgesic, antipyretic, and anti-inflammatory actions.


The drug entity utilizes Piroxicam as its core active ingredient, which is synthesized. Its pharmaceutical identity is defined by its structure as an advanced inclusion compound formulated with beta-cyclodextrin. Cyclodex is typically prepared for the oral route of administration, manufactured as capsules, tablets, or effervescent tablets, allowing for systemic delivery of the therapeutic compound. This specific formulation is often positioned to address scenarios demanding a fast onset of relief, such as acute pain flare-ups.


Composition and General Purpose

The medicine is composed of the active substance Piroxicam and the excipient beta-cyclodextrin, which acts as a host molecule to form the specialized molecular inclusion compound. Beta-cyclodextrin is deliberately incorporated to enhance the physical and chemical performance of the active drug, specifically due to Piroxicam's low solubility in water.


The unique complexation strategy with beta-cyclodextrin ensures a dramatically enhanced solubility and dissolution rate of the active ingredient. This enhanced dissolution directly leads to quicker absorption, which is the primary differentiating factor of Cyclodex from standard Piroxicam preparations. The general purpose of Cyclodex is to leverage its potent analgesic and anti-inflammatory properties to relieve symptoms like acute pain, swelling, and stiffness, offering a fast-acting option for patients requiring prompt symptom moderation.

What side effects are possible with Cyclodex?

Possible side effects and safety information for Cyclodex

The safety profile for Cyclodex (a class of compounds including alpha-, beta-, and gamma-cyclodextrins and their derivatives) is primarily determined by the specific derivative, the dose/concentration, and the route of administration.

Adverse Reaction Summary

System-Organ Class Clinically Significant Adverse Reaction
Renal/Urinary Nephrotoxicity (renal tubular degeneration/vacuolation) is the most serious risk, primarily associated with the intravenous (IV) administration of certain parent cyclodextrins (like alpha- and beta-CD) or certain derivatives (like RAMEB-beta-CD) at high doses.
Gastrointestinal Diarrhea and cecal enlargement (observed in animal studies) are possible effects, typically occurring only at very high oral doses exceeding regulatory-defined safe thresholds.
Ocular/Otic Ototoxicity (hearing loss) and toxicity to the corneal epithelium have been reported with the use of specific derivatives at high concentrations, often in the context of being used as an active therapeutic agent rather than an excipient.

Safety Considerations and Restrictions

Dose-Related Patterns: Adverse effects are fundamentally dose-dependent. Regulatory agencies, such as the European Medicines Agency (EMA), have established Permitted Daily Exposure (PDE) or safe concentration thresholds for various Cyclodex derivatives, below which adverse reactions are not expected.

Population-Specific Restrictions:

  • Renal Impairment: Intravenous use of certain cyclodextrin excipients, such as sulfobutylether-beta-cyclodextrin (SBE-beta-CD) and hydroxypropyl-beta-cyclodextrin (HP-beta-CD), is not recommended in patients with severe renal impairment (e.g., creatinine clearance below 30 mL/minute) due to the potential for the excipient to accumulate. Accumulation risk also warrants caution in newborns and infants.
  • Route of Administration: Parent cyclodextrins (alpha- and beta-CD) are generally contraindicated for intravenous use due to the risk of renal damage.

This official safety documentation establishes that the understanding of risks for Cyclodex compounds is structured around exceeding safe dose limits and using derivatives inappropriate for the intended route of administration. The primary safety focus is on the potential for renal toxicity following systemic exposure, necessitating dose limitations and specific warnings for renally impaired patient populations.

Overdose and Emergency Response

Cyclodex overdose is officially associated with severe systemic toxicity that necessitates immediate medical intervention. If an overdose is suspected, seek immediate medical attention or call emergency services. Urgent help is mandated if the person collapses, experiences a seizure, has difficulty breathing, or cannot be awakened.


Documented Overdose Manifestations

System Signs and Symptoms
Gastrointestinal Nausea, vomiting, abdominal pain, diarrhea, and potentially bleeding (bloody or tarry stools).
Neurological Drowsiness, severe headache, confusion, agitation, and convulsions (seizures).

Severe Outcomes and Management

Official regulatory documents define the overdose profile by documenting the risk of life-threatening outcomes, including severe gastrointestinal bleeding, acute renal failure (little to no urine output), hypotension (shock), and coma. Individuals with pre-existing kidney or liver impairment are noted as having increased susceptibility to severe effects.

The regulatory profile explicitly states that no specific antidote is known for Piroxicam overdose. Management focuses on providing symptomatic and supportive treatment. This may include the administration of activated charcoal, gastric lavage, and continuous monitoring of vital signs, blood tests, and cardiac function (ECG) in a hospital setting.

Therapeutic Uses of Cyclodex

Cyclodex: Main Therapeutic Applications

Cyclodex is a formulation that has been evaluated as an important therapeutic option for specific conditions. Its use is primarily indicated for the short-term relief of mild to moderately severe acute pain in adults. It may help reduce symptoms such as discomfort and inflammation associated with various acute musculoskeletal conditions.

For certain ophthalmic preparations, a version of Cyclodex (containing a combination of active ingredients) is used to assist in eye examinations by helping to enlarge the pupil. Furthermore, it may be prescribed in these contexts to support the reduction of pain and irritation related to particular eye conditions. All prescriptions for Cyclodex are based on the specific formulation and active pharmaceutical ingredient it contains, and its benefits are confined to symptom management rather than addressing the underlying disease progression.


Quick Facts

  • Acute Pain: Used to help relieve symptoms of mild to moderately severe acute pain.
  • Inflammation: Intended to help manage inflammation and discomfort in the short-term.
  • Ophthalmic Use: May be prescribed to support eye examinations and manage related pain/irritation.

Eligibility and Restrictions for Use

Cyclodex is not suitable for all patient populations due to specific rules established by regulatory authorities. The eligibility profile defines who may use the medicine and who is formally prohibited.

Contraindicated Populations

Use of Cyclodex is contraindicated (must not be used) in patients with the following conditions or history:

  • Known hypersensitivity to Piroxicam, aspirin, or other Nonsteroidal Anti-inflammatory Drugs (NSAIDs) that cause allergic reactions (e.g., asthma, urticaria).
  • Active gastrointestinal (GI) ulceration, bleeding, or perforation, or a history of these serious GI events.
  • Severe uncontrolled heart failure, severe hepatic impairment, or severe renal impairment.
  • During the last trimester of pregnancy (after 30 weeks gestation) and for pain in the setting of CABG surgery.
  • Concomitant use with other systemic NSAIDs.

Age- and Condition-Based Restrictions

Population Group Eligibility Status Restriction Details
Children/Adolescents (Under 18) Not Recommended / Contraindicated Safety and efficacy have not been established [Source 1.5].
Older Adults (Over 80) Administration Avoided Use is generally avoided; patients over 70 years require heightened caution [Source 1.9].
Pregnancy/Lactation Contraindicated / Not Recommended Contraindicated in the last trimester; not recommended during the first two trimesters or while breastfeeding [Source 3.4].

Use is also conditional and requires careful evaluation for patients with established cardiovascular disease, uncontrolled hypertension, or other bleeding disorders. All eligibility status classifications are based strictly on official government-approved prescribing information.

What should I know about interactions with other medicines?

Cyclodex Interactions with other medicines and products

Official regulatory information describes specific interaction patterns for Cyclodex (Piroxicam) which define co-administration constraints, including absolute prohibitions and requirements for close monitoring.

Classification Constraint / Interacting Substance
Contraindicated Treatment of peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.
Not Generally Recommended Co-administration with analgesic doses of Aspirin due to increased gastrointestinal risk.

Interactions Affecting Drug Levels:

  • Lithium and Digoxin: Cyclodex may cause an elevation of plasma levels for both Lithium and Digoxin by reducing their renal clearance.
  • Methotrexate: The product can decrease the elimination of Methotrexate, potentially leading to increased systemic exposure.
  • CYP2C9 Metabolizers: Individuals who are poor metabolizers of the CYP2C9 enzyme may exhibit higher systemic concentrations of Piroxicam due to reduced metabolic clearance.

Pharmacodynamic and Efficacy Interactions:

  • Anticoagulants (e.g., Warfarin) and Antiplatelet Agents: Co-administration significantly increases the risk of serious gastrointestinal bleeding due to additive effects.
  • Antihypertensives (e.g., ACE Inhibitors, ARBs, Diuretics): Cyclodex may diminish the efficacy of these medicines by reducing their blood pressure-lowering or natriuretic effects. The risk of renal function deterioration is heightened when ACE Inhibitors or ARBs are combined with Cyclodex in elderly or renally impaired patients.

Food and Substance Impact: Administration of the Piroxicam-beta-cyclodextrin complex with food is documented to delay the rate of absorption but does not alter the total amount of drug absorbed. Co-administration with common Antacids has been reported to show no clinically significant effect on Piroxicam plasma levels.

Mechanism of Action

How Cyclodex Works

The mechanism of Cyclodex focuses on molecular inhibition of enzyme activity and subsequent modulation of physiological signaling, leveraging an advanced kinetic strategy to accelerate the onset of action.


Enzyme Inhibition and Prostaglandin Suppression

The core mechanism involves the active ingredient, Piroxicam, acting as a non-selective reversible inhibitor of the Cyclooxygenase (COX) enzymes, both COX-1 and COX-2. This inhibition directly interrupts the Arachidonic Acid Cascade, resulting in a reduction in the synthesis of prostaglandins—key lipid mediators of nociceptive sensitization and local inflammatory processes.


Modulation of Nociceptive and Thermoregulatory Pathways

Suppression of prostaglandin production results in the attenuation of peripheral nociceptor sensitization and modulates the central hypothalamic temperature set point. These actions correspond to the physiological consequences linked to the drug's molecular activity.


Kinetics Acceleration via Inclusion Complex

The pharmaceutical formulation includes beta-cyclodextrin, which forms an inclusion complex with Piroxicam. This specific physical mechanism increases the drug's dissolution and absorption rate. This acceleration increases the rate at which the necessary concentration for COX enzyme inhibition is achieved, which determines the rapid onset of molecular activity.

Dosage and Administration Information

How to Use Cyclodex

This section outlines the standardized usage principles for Cyclodex (Piroxicam-beta-cyclodextrin), focusing exclusively on administration patterns and dosage regimens.


Official Administration Guidelines

Cyclodex is formulated for oral administration, available as capsules, tablets, and effervescent tablets. The typical approach involves a once-daily schedule, which reflects the prolonged half-life of the active ingredient. For maintenance, the dose range is generally 10 mg to 20 mg daily, with 20 mg being the maximum recommended daily dose for continuous use.

Dosing Principles

To manage acute conditions, the initial regimen may involve 40 mg daily for the first two days, followed by a reduction to 20 mg daily for the remainder of the short-term treatment course. The fundamental principle of use requires adherence to the lowest effective dosage for the shortest duration necessary. For continuous treatment, the patient's requirement for the medication must be formally reviewed within 14 days of initiation.

Intake Conditions and Adjustments

Administration is generally recommended with or immediately after food. Tablets may be scored to facilitate a 10 mg dose when appropriate. Use is not recommended for children under 12 years of age. For older adults, a dose reduction, potentially to 10 mg daily, and a limitation on treatment duration are considered necessary procedural steps.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cyclodex


Evidence for Use in Acute Pain and Inflammation

The research landscape for Cyclodex focuses heavily on its use in situations where patients experience episodic or acute changes in pain and inflammation, such as following surgery, dental procedures, or acute flare-ups of conditions. Studies conducted during periods of increased symptom activity often rely on short-term, randomized controlled trials (RCTs). These RCTs are relevant because research examined how symptoms are measured in the observed populations when Cyclodex was observed in trials that included a placebo (an inactive substance) and other established compounds.

These trials were largely applied in research contexts involving short-term symptom patterns. Researchers monitored outcomes related to physical discomfort, primarily using patient-reported scores to describe the perceived discomfort and intensity of the pain. Findings often described patterns observed in the studies regarding the timing of when symptom scores were measured compared to standard Piroxicam formulations.


Evidence for Symptom Management in Chronic Conditions

Cyclodex was studied for its potential role in managing symptoms of conditions characterized by functional limitations, such as osteoarthritis or chronic back pain. Research exploring short-term symptom changes in these settings often involved intermediate-term clinical trials, typically running for several weeks. Studies examined pain intensity, stiffness (such as morning stiffness), and outcomes related to daily functioning or activity level.

Despite the intermediate-term follow-up in some trials, long-term effects are not fully established. Comparative evidence is lacking against the full range of newer NSAID formulations available today. Consequently, there is limited information for long-term outcomes concerning the maintenance of functional capacity and the effects of continuous use on the underlying chronic condition.


Research Focus on Specialized Delivery and Absorption

The unique formulation of Cyclodex (Piroxicam complexed with beta-cyclodextrin) was studied for research exploring drug behavior. Studies have primarily been conducted in vitro (in laboratory settings) and in preclinical animal models. This research examined how the pharmaceutical formulation affects the solubility and dissolution rate of the active ingredient, Piroxicam.

Findings indicate patterns related to absorption kinetics and bioavailability in the models studied. However, certainty remains low when translating this formulation science directly to widespread human clinical outcomes for specialized applications. Large-scale human clinical trial data for certain groups remain insufficient.

Frequently Asked Questions (FAQ)

Common questions about Cyclodex (FAQ)

Q: Does Cyclodex have a boxed warning (Black Box Warning) in its official labeling?

A: Yes, the FDA requires a Boxed Warning for the active ingredient in its official labeling. This warning describes the potential risk of serious cardiovascular thrombotic events, such as heart attack and stroke. It also highlights the risk of serious, potentially fatal gastrointestinal bleeding, ulceration, and perforation.

Q: What is the most common side effect listed for Cyclodex in the prescribing information?

A: Official product information indicates that common adverse reactions (seen in over 2% of patients in trials) include gastrointestinal issues like nausea, abdominal pain, diarrhea, and constipation. Other common effects listed are headache, dizziness, rash, and swelling (edema).

Q: Are minor issues like dry mouth or mild headache expected when starting Cyclodex?

A: Regulatory documents list headache and dizziness as common side effects that were observed in clinical trials. While these symptoms may be experienced, dry mouth is not consistently listed among the frequently reported adverse events.

Q: Is it safe to consume alcohol in moderation while taking Cyclodex?

A: Official warnings describe that combining alcohol with this class of medicine significantly increases the risk of serious gastrointestinal bleeding, ulceration, and perforation. Official guidance describes that co-administration of alcohol is generally not recommended or advised due to the severity of this risk.

Q: Does Cyclodex interact with common over-the-counter pain relievers like ibuprofen or acetaminophen?

A: Official labeling describes that co-administration with other systemic nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, is generally considered to increase the risk of serious gastrointestinal side effects. No major regulatory warning is explicitly listed for co-administration with acetaminophen (paracetamol).

Q: Do official sources warn about driving or operating machinery while taking Cyclodex?

A: Dizziness is listed as a common side effect in the clinical trial data for the active substance. Official sources describe that if an individual experiences dizziness or other central nervous system effects, caution is warranted when operating machinery or driving.

Q: Is it necessary to take Cyclodex at the exact same time every day?

A: The medicine is prescribed for a once-daily schedule. Consistency in taking the medication at a similar time each day may be beneficial to help maintain stable drug levels in the body. The official label does not mandate an exact time.

Q: Is it true that I should stop taking Cyclodex once my symptoms have improved?

A: The fundamental principle of use, as described in regulatory guidance, is to use the lowest effective dose for the shortest duration necessary. Treatment is often short-term, and continued use beyond 14 days typically requires a formal re-evaluation by a health professional.

Q: Is a generic version of Cyclodex available, and is it considered equally effective?

A: The active ingredient in Cyclodex, Piroxicam, has been available in generic form since 1992 and is manufactured globally under various brand names. Generic versions are required to contain the same active ingredient as the brand-name product, although the inactive components may differ.

Q: Can Cyclodex cause weight gain or weight loss?

A: Studies indicate that nonsteroidal anti-inflammatory drugs (NSAIDs) may cause fluid retention or edema (swelling), which can be observed as unusual weight gain. Weight loss is not generally reported as a typical side effect of the medicine.

Q: Does Cyclodex affect energy levels or cause fatigue?

A: Fatigue, or a lack of strength, is noted in adverse event data for the active substance. It is also mentioned that symptoms such as unusual tiredness may be an indication of more serious underlying issues, such as liver or kidney problems.

Q: Can Cyclodex tablets or capsules be crushed or split to make them easier to swallow?

A: The tablet form of the medicine may be scored (marked) to allow for easier dose splitting when a lower dosage is needed. General guidance indicates that capsules should not be opened or crushed, and the special formulation should not be altered unless specifically instructed by a healthcare professional.

Q: What kind of medical tests are required before a patient starts taking Cyclodex?

A: Regulatory safety information indicates that monitoring of certain health parameters is recommended during treatment with NSAIDs. This may include checking blood pressure, kidney function, and blood cell counts (such as hemoglobin levels) due to associated risks in this drug class.

Q: Is the active ingredient in Cyclodex available in any over-the-counter products?

A: While the oral form of the active ingredient, Piroxicam, is primarily available by prescription, the ingredient itself is available as a prescription-free gel (0.5%) for topical use in some countries.

Q: Are there any special instructions for traveling with Cyclodex, like temperature control during a flight?

A: Official storage instructions state that the medicine must be stored at room temperature, in a cool, dry place, and protected from light and heat. Specific, detailed protocols regarding temperature control during air travel are not typically provided in the official regulatory documentation.

How should Cyclodex be stored and disposed of?

How to Store and Dispose of Cyclodex

Official regulatory documents define strict requirements for storing and disposing of Cyclodex (Piroxicam-beta-cyclodextrin) to maintain its stability and ensure safety.


Storage Requirements

Cyclodex must be stored in a cool, dry, and well-ventilated place at room temperature. It is essential to protect the medicine from light and heat, and the container must be kept tightly closed and stored in its original container.

For safety, the product should be secured and stored in an area accessible only to authorized persons, keeping it out of the reach of children.


Disposal Instructions

Disposal of unused or expired Cyclodex must be conducted in accordance with Federal, State, and Local regulation. The medicine should be taken to an approved waste disposal plant. It is strictly forbidden to dispose of the product into drains, surface water, or ground water.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cyclodex found in:

A-Z Index: